MADRIGAL PHARMACEUTICALS, INC. (MDGL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5588681057
Price
453.34 USD
Market cap
10.47 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
MADRIGAL PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 958.40 m USD |
| Operating income | -300.10 m USD |
| EBIT | -303.34 m USD |
| Net income | -288.28 m USD |
| Diluted EPS – continuing operations | -12.85 USD |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
More stocks
- Antero Midstream Corp (AM)
- Quantinuum Inc. Class A Common Stock (QNT)
- Camden Property Trust (CPT)
- Samsung Heavy Industries (010140.KS)
- Aisin Seiki Co Ltd (ASEKY)
- DROPBOX, INC. (DBX)
- ANA Holdings Inc (9202.T)
- RAMBUS INC (RMBS)
- Budweiser Brewing Company APAC Ltd (1876.HK)
- Edison SpA (EDNR.MI)
- Sime Darby Plantation Bhd (5285.KL)
- TORO CO (TTC)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.